

# Biosynthesis of hepoxilins: evidence for the presence of a hepoxilin synthase activity in rat insulinoma cells

Pattabhiraman Shankaranarayanan, Roberto Ciccoli, Santosh Nigam\*

*Eicosanoid Research Division and Centre for Experimental Gynecology and Breast Research, University Medical Centre Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, D-12200 Berlin, Germany*

Received 17 December 2002; revised 4 February 2003; accepted 4 February 2003

First published online 19 February 2003

Edited by Jacques Hanoune

**Abstract** The 12(*S*)-lipoxygenase (12-LOX) pathway of arachidonic acid (AA) metabolism after dioxygenation to 12(*S*)-hydroperoxy-eicosatetraenoic acid is bifurcated in a reduction route to formation of 12(*S*)-hydroxy-eicosatetraenoic acid (12-HPETE) and an isomerization route to formation of hepoxilins. Interestingly, we found that the rat insulinoma RINm5F cells, which are devoid of cytoplasmic glutathione peroxidase (cGPx)/phospholipid hydroperoxide glutathione peroxidase (PHGPx), produce solely hepoxilin A<sub>3</sub> (HXA<sub>3</sub>). Since HXA<sub>3</sub> synthesis was abolished in heat-denatured or cGPx- or PHGPx-transfected cells, it was tempting to speculate that a HXA<sub>3</sub> synthase activity regulated by cGPx/PHGPx is present. To confirm this assumption we incubated AA with HeLa cells overexpressing the rat leukocyte-type 12-LOX. Neither HXA<sub>3</sub> nor 12(*S*)-HETE were detected due to abundance of cGPx/PHGPx. But, pretreatment of transfected cells with diethyl maleate, an inhibitor of glutathione and PHGPx, restored HXA<sub>3</sub> synthase and 12-LOX activities. Thus, we conclude, that cells containing rat leukocyte-type 12-LOX also possess an intrinsic HXA<sub>3</sub> synthase activity, which is activated by inhibition of cGPx/PHGPx. In normal cells HXA<sub>3</sub> is down-regulated by cGPx/PHGPx, but, it is persistently activated in oxidatively stressed cells deficient in cGPx/PHGPx, such as RINm5F.

© 2003 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.

**Key words:** Arachidonic acid;  
Cytoplasmic glutathione peroxidase;  
Phospholipid hydroperoxide glutathione peroxidase;  
Hepoxilins; Hepoxilin A<sub>3</sub> synthase;  
Leukocyte-type 12(*S*)-lipoxygenase; RINm5F cells

## 1. Introduction

The 12(*S*)-lipoxygenase (12-LOX) pathway of arachidonic acid (AA) metabolism after the dioxygenation to 12(*S*)-hydro-

peroxy-eicosatetraenoic acid (12(*S*)-HPETE) is bifurcated in a reduction route to formation of 12(*S*)-hydroxy-eicosatetraenoic acid (12(*S*)-HETE) and an isomerization route to formation of hepoxilins. Hepoxilins are hydroxy-epoxy derivatives of AA, mainly observed as hepoxilin A<sub>3</sub> (HXA<sub>3</sub>) (8*S*/*R*-hydroxy-11,12-epoxyeicosa-5*Z*,9*E*,14*Z*-trienoic acid) and hepoxilin B<sub>3</sub> (HXB<sub>3</sub>) (10*S*/*R*-hydroxy-11,12-epoxyeicosa-5*Z*,8*Z*,14*Z*-trienoic acid) [1] and references therein). HXA<sub>3</sub> is a potent biologically active lipid, which stimulates glucose-induced secretion of insulin in rat pancreatic islets, hyperpolarizes the membrane potential and controls the inhibitory postsynaptic potential in aplysia and mammalian neurons, and regulates the cell volume in platelets and aplysia neurons by activation of K<sup>+</sup> channels [1]. It has also been shown to augment the intracellular calcium level [2], the heat shock protein72 (HSP<sup>72</sup>) [1] as well as AA release and diacylglycerol in human neutrophils [3].

AA metabolism in mammalian cells is known to be regulated by glutathione peroxidases (GPx) [4–8], which reduce the hydroperoxy fatty acids emanating from LOXs- or cyclooxygenases-catalyzed reactions to corresponding alcohols. Among various forms of GPx, two different isoforms, cGPx, the cytoplasmic isoform, and PHGPx (phospholipid hydroperoxide glutathione peroxidase), the membranous isoform, have been recently reported by us to regulate the 12-LOX-mediated eicosanoid metabolism in platelets [9]. Because GPx and hepoxilin-forming catalysts compete for the same substrate, it can be conjectured that the overall activity of glutathione peroxidases, or in other words the overall hydroperoxide tone, determines the rate of hepoxilin formation. Consequently, inhibition of both cGPx and PHGPx by iodoacetate has been shown to enhance the synthesis of hepoxilins with concomitant reduction of 12(*S*)-HETE production [9]. This indicated a shift in conversion of 12(*S*)-HPETE from the reduction pathway to the so-called isomerization pathway. Although PHGPx activity contributes only 2% to the total 12(*S*)-HPETE reductase activity (mostly cGPx activity) its share in reducing the 12(*S*)-HPETE is far more pronounced as found in cGPx-depleted selenium-deficient UT7 cells [9] and cGPx knock-out mice [10].

The biosynthesis of hepoxilins by isomerization pathway is highly controversial. In order to elucidate the mechanism Dr. Pace-Asciak's group performed a number of mechanistic studies during the last decade and proposed an enzymatic pathway for the formation of hepoxilins. His proposal was based on the stereoselective conversion of 12(*S*)-HPETE into 8(*S*)- and 8(*R*)-epimers of HXA<sub>3</sub> by rat pineal gland [11], while 12(*R*)-HPETE remained unmetabolized. Moreover, the conversion

\*Corresponding author. Fax: (49)-30-8445 2467.

E-mail address: [nigam@zedat.fu-berlin.de](mailto:nigam@zedat.fu-berlin.de) (S. Nigam).

**Abbreviations:** DEM, diethyl maleate; cGPx, cytoplasmic glutathione peroxidase; PHGPx, phospholipid hydroperoxide glutathione peroxidase; GSH, glutathione; 12(*S*)-HETE, 12(*S*)-hydroxy-eicosatetraenoic acid; 12(*S*)-HPETE, 12(*S*)-hydroperoxy-eicosatetraenoic acid; HXA<sub>3</sub>, hepoxilin A<sub>3</sub> or 8*S*/*R*-hydroxy-11,12-epoxyeicosa-5*Z*,9*E*,14*Z*-trienoic acid; HXB<sub>3</sub>, hepoxilin B<sub>3</sub> or 10*S*/*R*-hydroxy-11,12-epoxyeicosa-5*Z*,8*Z*,14*Z*-trienoic acid; 12-LOX, 12(*S*)-lipoxygenase; Me-TMS, methyl-trimethylsilyl; TrXA<sub>3</sub>, trioxilin A<sub>3</sub>

of AA by the pineal gland resulted in the formation of HXA<sub>3</sub> of the native 11(*S*),12(*S*)-configuration of epoxide, showing the presence of 12-LOX in the pineal tissue [12], which led to the conclusion that the biosynthesis of hepxilins is only possible in cells and tissues that contain 12-LOX. However, a clear-cut evidence for the presence of HXA<sub>3</sub> synthase activity is not yet presented. In the present study, we have shown that RINm5F rat insulinoma cells contain a heat-sensitive leukocyte-type 12-LOX enzyme, which expresses HXA<sub>3</sub> synthase activity and is capable of transforming AA or 12(*S*)-HPETE selectively to HXA<sub>3</sub>. Furthermore, this activity is regulated by selenoenzymes, e.g. cGPx and PHGPx. To prove the regulation by selenoenzymes, we used native RINm5F cells, which are devoid of cGPx and PHGPx [13] and produce large amounts of HXA<sub>3</sub> when incubated with AA. The HXA<sub>3</sub> synthesis was however abolished when cells stably transfected with cGPx or PHGPx were used.

## 2. Materials and methods

### 2.1. Cell culture

RINm5F, rat insulinoma cells (ATCC, Washington, DC, USA), were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. The cells were grown in humidified incubators at 37°C with 5% CO<sub>2</sub>. RINm5F cells stably transfected with cGPx, a kind gift from Dr. Tiedge, Hannover, Germany, were cultured in the same culture medium as above, but supplemented with 400 µg/ml geneticin (Invitrogen) and 10 nM sodium selenite.

### 2.2. Assay of HXA<sub>3</sub> synthase activity

The hepxilin synthase A<sub>3</sub> activity was measured by incubating the lysate from RINm5F cells with 100 µM AA in a volume of 200 µl for 30 min at 37°C and measuring the formation of hepxilins using GC-MS or HPLC. The reaction was stopped by acidification with 1 N HCl to pH 3.0. The reaction mixture was allowed to incubate at room temperature in acidic conditions for 15 min before extracting the lipids twice with 3 volumes of ethyl acetate. The lipid fractions were extracted with ethyl acetate, evaporated to dryness under nitrogen, reconstituted in *n*-hexane and analyzed with gas chromatography-mass spectrometry (GC-MS).

### 2.3. GC-MS

The lipids were converted to their methyl esters by the addition of 300 µl ethereal diazomethane for 5 min. Thereafter the samples were evaporated to dryness, 30 µl *N*-methyl-*N*-(trimethylsilyl)trifluoroacetamide was added and the mixture was derivatized by heating at 60°C for 30 min. GC-MS was performed by means of a Varian Saturn 4D GC-MS-MS system equipped with a Supelco DB5-MS column (30 m×0.25 mm; 0.25 µm d<sub>f</sub>). The temperature program was started at 150°C increasing to 250°C within 10 min with a rate of 10°C/min. The temperature of injector and transfer line were 230°C and 220°C respectively.

### 2.4. Detection of HXA<sub>3</sub> in RINm5F cells by HPLC

RINm5F cells (10×10<sup>6</sup> cells) were harvested and resuspended in 100 µl 0.1 M sodium phosphate buffer (pH 7.4). 100 µM AA was added and the reaction was allowed to proceed at 37°C for 30 min. The reaction was stopped and the lipids were extracted by the addition of ether-methanol-1 M citrate (135:15:1, v/v). The organic phase was evaporated and the residue was taken into 100 µl ethyl acetate and derivatized by the addition of 9-anthryldiazomethane (100 µg/reaction) [11]. The reaction mixture was stirred at room temperature for 1 h. The ethyl acetate was then evaporated, the residue was reconstituted in the solvent system and the lipids were loaded onto a Novapak C<sub>18</sub> (250×46 mm; 5 µm particle size) reverse phase column. Acetonitrile-methanol-water (90:6:4 v/v) was used as mobile phase. The eluate was UV-monitored using a Shimadzu diode-array detector set at 254 nm and fluorescence-monitored (excitation 254 nm, emission 400 nm) using a Shimadzu fluorescence detector.

## 3. Results

### 3.1. RINm5F cells express hepxilin synthase-like activity

Cultured RINm5F cells were incubated with 100 µM AA for 20 min and the products were analyzed as ADAM ester derivatives by HPLC monitoring fluorescence detection (see Section 2). As shown in Fig. 1A, a distinct HXA<sub>3</sub> peak was observed, which appeared at the same retention time as the authentic standard (panel III). Upon longer incubation, e.g. 40 min, HXA<sub>3</sub> peak was substantially reduced and a more polar peak appeared (not shown), which has been earlier shown to characterize the hydrolysis products of HXA<sub>3</sub>, i.e. 8(*S*/*R*),11(*R*),12(*S*)-trihydroxy-eicosa-5*Z*,9*E*,14*Z*-trienoic acid and 10(*S*/*R*),11(*R*),12(*R*)-trihydroxy-eicosa-5*Z*,8*Z*,14*Z*-trienoic acid, trivially known as trioxilins A<sub>3</sub> (TrXA<sub>3</sub>) [1]. As these hepxilins are hydrolyzed by cellular epoxide hydrolases, HXA<sub>3</sub> formation was determined in RINm5F cells pretreated with 100 µg/ml trichloro-propylene oxide (TCPO), an inhibitor of epoxide hydrolases. After 40 min incubation with AA a significant increase in HXA<sub>3</sub> formation was observed




Fig. 1. Representative profiles of UV-detectable synthesis of HXA<sub>3</sub> untreated (A) and TCPO-treated RINm5F cells. A: Native RINm5F cells were incubated with 100 µM AA at 37°C for 30 min. The lipids were extracted by organic solvents and derivatized by the addition of 100 µg 9-anthryldiazomethane. The lipids were separated by RP-HPLC and detected at 254 nm. Panels I and II represent HXA<sub>3</sub> and HXB<sub>3</sub> standard, respectively. Panel III represents the formation of HXA<sub>3</sub> alone from the reaction of AA with RINm5F cells. Peak next to HXA<sub>3</sub> is not related to AA metabolism via 12-LOX pathway. B: RINm5F cells with or without pretreatment of 10 µM TCPO, an epoxide hydrolase inhibitor, were incubated with 100 µM AA and the samples were processed as described in (A). Significant increase in HXA<sub>3</sub> formation can be seen in TCPO-treated cells.




Fig. 2. Representative mass chromatograms ( $[M]^+$ ) of Me-TMS derivative of TrXA<sub>3</sub> obtained from the transformation of AA by RINm5F cells. Incubation of RINm5F cells with AA were carried out as described in Fig. 1A and Me-TMS derivatives were analyzed by GC-MS (see Section 2). A: Panels I and II show the representative mass chromatograms of Me-TMS derivative of standards TrXA<sub>3</sub> ( $m/z$  243) and HXB<sub>3</sub> ( $m/z$  269), respectively. Panel III shows the representative mass chromatogram of Me-TMS derivative of TrXA<sub>3</sub> obtained from the transformation of AA by native RINm5F cells. Panel IV shows the abrogation of TrXA<sub>3</sub> by scanning the mass chromatogram of Me-TMS derivative of TrXA<sub>3</sub> obtained from the reaction of AA with heat-denatured RINm5F cells. B: Electron impact mass spectra of the Me-TMS derivatives of TrXA<sub>3</sub> and HXB<sub>3</sub> showing characteristic ions  $m/z$  243 and  $m/z$  269, respectively.




Fig. 3. Representative mass chromatograms ( $[M]^+$ ) of Me-TMS derivative of TrXA<sub>3</sub> and 12(S)-HETE obtained from the transformation of AA by native and cGPx-transfected RINm5F cells. Panel I shows the representative mass chromatogram of Me-TMS derivative of TrXA<sub>3</sub> ( $m/z$  243) obtained from the transformation of AA by native RINm5F cells. Panel II shows the abrogation of TrXA<sub>3</sub> by scanning the mass chromatogram of Me-TMS derivative of TrXA<sub>3</sub> obtained from the reaction of AA with cGPx-transfected RINm5F cells. Panel III shows the representative mass chromatogram ( $m/z$  295) of Me-TMS derivative of 12(S)-HETE formed from the reaction of AA with cGPx-transfected RINm5F cells.

(Fig. 1B) without appearance of a polar peak. To confirm the chemical structure of HXA<sub>3</sub> from RINm5F cells, the incubation mixture was extracted as described in Section 2, the residue acid-hydrolyzed (to transform HXA<sub>3</sub> to stable TrXA<sub>3</sub>)

and converted to methyl-trimethylsilyl (Me-TMS) derivatives for GC-MS analysis. As shown in Fig. 2 (panel III), a singular peak characterizing TrXA<sub>3</sub> was observed, but no HXB<sub>3</sub> was detected, indicating the absence of heme-catalyzed reaction.




Fig. 4. Production of HXA<sub>3</sub> from the transformation of AA by HeLa cells transfected with rat leukocyte-type 12-LOX-cDNA. Panels I and II show the abrogation of TrXA<sub>3</sub> as well as 12(S)-HETE by scanning the mass chromatogram of Me-TMS derivatives of TrXA<sub>3</sub> ( $m/z$  243) and 12(S)-HETE ( $m/z$  295), respectively, obtained from the reaction of AA with HeLa cells transfected with rat leukocyte-type 12-LOX. Panels III and IV show the effect of inhibition of GSH and PHGPx by 2 mM DEM on the formation of TrXA<sub>3</sub> as well as 12(S)-HETE, respectively. Representative mass chromatograms of Me-TMS derivatives of TrXA<sub>3</sub> ( $m/z$  243) and 12(S)-HETE ( $m/z$  295), show clearly the formation of HXA<sub>3</sub> as well as 12(S)-HETE by transfected HeLa cells.



Strikingly, the heat-denatured (90°C for 10 min) cell lysate failed to produce any HXA<sub>3</sub>, pinpointing the enzymatic pathway of its formation (Fig. 2, panel IV). The absence of 12-LOX activity as well (not shown) supported the earlier assumption by Pace-Asciak's group that the HXA<sub>3</sub> synthase activity is only present in cells that contain 12-LOX activity [12].

### 3.2. GPx inhibit the formation of HXA<sub>3</sub>

Recently, we showed the prominent role of PHGPx as a 12(S)-HPETE reductase in human platelets [9]. In absence of cGPx the reduction 12(S)-HPETE to 12(S)-HETE was taken over by PHGPx. But, inactivation of both selenoenzymes cGPx and PHGPx by iodoacetate led to accumulation of 12(S)-HPETE, the metabolism of which was consequently diverted to HXA<sub>3</sub> and HXB<sub>3</sub> formation. Since RINm5F cells are almost devoid of cGPx and PHGPx [13], as expected these cells synthesized HXA<sub>3</sub> when incubated with AA as substrate (Fig. 3, panel I). Conversely, we assumed that the presence of GPx should diminish the formation of HXA<sub>3</sub> (RINm5F cells do not produce HXB<sub>3</sub>!). Indeed, upon incubation with AA cultured RINm5F cells, stably transfected with cGPx did not produce any HXA<sub>3</sub> as determined by GC-MS (Fig. 3, panel II). However, due to the down-regulation of 12-LOX by cGPx very little 12(S)-HETE was detectable (Fig. 3, panel III). Incubation with 12(S)-HPETE of native or cGPx-transfected RINm5F cells reproduced identical results as with AA (not shown). Similar results, albeit less pronounced, were obtained with PHGPx-transfected RINm5F cells (not shown).

### 3.3. Rat leukocyte-type 12-LOX possesses intrinsic HXA<sub>3</sub> synthase-like activity

To investigate if this regulatory mechanism by GPx of 12-LOX possessing intrinsic HXA<sub>3</sub> synthase activity is a common phenomenon in other cells, we transfected rat leukocyte-type 12-LOX-cDNA in HeLa cells, which show low expression of 12-LOX. Upon incubation of cultured transfected cells with AA, neither 12(S)-HETE nor HXA<sub>3</sub> was produced, suggesting the complete down-regulation of 12-LOX by selenoenzymes abundantly present in the cell (Fig. 4, panels I and II). However, pretreatment of 12-LOX-transfected cells with 2 mM diethyl maleate (DEM), which depletes cellular glutathione (GSH) and thus inhibits PHGPx [7], caused significant enhancement of HXA<sub>3</sub> synthesis (Fig. 4, panel III), but also a little formation of 12(S)-HETE. As no HXB<sub>3</sub> formation was detected in GSH- and GPx-depleted cells, an up-regulation of HXA<sub>3</sub> synthase activity seems to be evident.

## 4. Discussion

Lipoxygenases are bifunctional enzymes exhibiting both fatty acid dioxygenase and lipohydroperoxidase activities. The lipohydroperoxidase activity, unlike the dioxygenase activity, does not require oxygen insertion. Among various reports on the enzymatic conversion of AA with different lipoxygenases, it has been, for instance, clearly demonstrated that both soybean lipoxygenase-1 [14] and reticulocyte-type 15-lipoxygenase [15] are capable of converting hydroperoxy-polyenoic fatty acids to their hydroxy-epoxy derivatives. Thus, 15-LOX has been shown to convert 15-hydroperoxy fatty acids and AA to epoxy-leukotrienes [15,16]. Also, 15-LOX from garlic roots converted AA, but not 12(S)-HPETE,

to 14,15-hepoxilins [17]. Although platelet-type 12-LOX does not possess any lipohydroperoxidase activity, Bryant et al. showed in the lysate from selenium-deficient platelets the formation of hydroxy-epoxy derivatives of AA, currently known as TrXA<sub>3</sub> and TrXB<sub>3</sub> [18]. Later, using hemin and hemoglobin Pace-Asciak et al. demonstrated that the isomerization of 12(S)-HPETE to HXA<sub>3</sub> and HXB<sub>3</sub> is heme-catalyzed [19]. Recently, our laboratory also found that the conversion of AA to HXA<sub>3</sub> and HXB<sub>3</sub> in platelets, as reported by Bryant et al. [8], is heme- and not enzyme-catalyzed, and that cGPx and PHGPx prevent the detection of hepoxilins by diverting the 12(S)-HPETE → hepoxilin pathway to 12(S)-HPETE → 12(S)-HETE pathway [9], thus revealing the importance of selenoenzymes in the regulatory network of AA metabolism.

RINm5F rat insulinoma cells, which possess leukocyte-type 12-LOX and are devoid of cGPx and PHGPx [13], produced only HXA<sub>3</sub> when incubated with AA (Fig. 1A). Moreover, no HXA<sub>3</sub> was detected in the lysate from heat-inactivated cells (Fig. 2A, panel IV). But, cultured cells stably transfected with cGPx or PHGPx-cDNA did not show any formation of HXA<sub>3</sub> (Fig. 3, panel II). These results pinpointed the presence of HXA<sub>3</sub> synthase-like activity in RINm5F cells and its regulation by GPx. Strikingly, 12-LOX activity was also absent in heat-denatured RINm5F cells (not shown), which supported the assumption of Pace-Asciak's group that the enzymatic formation of HXA<sub>3</sub> requires inevitably the presence of 12-LOX enzyme [20]. The fact that HeLa cells overexpressing rat leukocyte-type 12-LOX did not produce any HXA<sub>3</sub> and 12(S)-HETE under normal conditions, suggests the complete down-regulation of 12-LOX activity by the abundantly present cGPx and PHGPx. But, drastic increase in the formation of HXA<sub>3</sub> upon treatment with DEM, which depletes cellular GSH and inhibits PHGPx thus elevating the overall hydroperoxide tone, added support to our assumption that the rat leukocyte-type 12-LOX possesses an intrinsic HXA<sub>3</sub> synthase activity. The latter was found to be finely tuned by cellular GPx cGPx and PHGPx. This regulation by GPx is in line with earlier observations reported for 5-, 12- and 15-LOX [4,6,8].

Normally, in various cell types the presence of GPx exerts the primacy of the reduction pathway over the hepoxilin pathway. In our experiments with HeLa cells overexpressing the rat leukocyte-type 12-LOX, selenoenzymes obviously diminished the cellular peroxide tone to such an extent that even a minimum peroxide level essential to trigger the activation of 12-LOX may not be present. Thus, an important message can be deduced from the above observations, that in most cell types under physiological conditions abundantly present selenoenzymes prevent the hepoxilin formation and divert the AA metabolism to the formation of 12(S)-HETE from intermediate 12(S)-HPETE. This means de facto that the formation of HXA<sub>3</sub> is only restricted to pathological cases, say to diseases with persistent oxidative stress, in which deficiency of selenoenzymes is prevalent. It should however be stressed that the mechanisms underlying the activation of HXA<sub>3</sub> synthase activity are primarily associated with GSH depletion and inhibition of GPx rather than with increase in reactive oxygen species. Since HXA<sub>3</sub> is known to be cell protective [1], its formation can be regarded as a counteraction to the permanent oxidative-stressed cellular status. Thus, synthesis of hepoxilins plays an important role in the processing of cellular hydro-

peroxides and hence in overall regulation of the 12-LOX pathway.

**Acknowledgements:** This study was supported by a Grant from the Deutsche Forschungsgemeinschaft, Bonn (Ni 242/27-1). Authors wish to thank Dr. Cecil Pace-Asciak for helpful discussions and suggestions. Authors also express their gratitude to Dr. Tiedge, MH Hannover, Germany for native and stably cGPx-transfected RINm5F cells, Dr. Colin Funk, Philadelphia, PA, USA for p12-LOX-cDNA and Dr. Brigelius Flohe, Potsdam, Germany for PHGPx plasmid. GC-MS and LC-MS assistance by Günter Baude, Schering AG, Berlin, Germany is gratefully acknowledged.

## References

- [1] Pace-Asciak, C.R. (1994) *Biochim. Biophys. Acta* 1215, 1–8.
- [2] Sutherland, M., Schewe, T. and Nigam, S. (2000) *Biochem. Pharmacol.* 59, 435–440.
- [3] Nigam, S., Nodes, S., Cichon, G., Corey, E.J. and Pace-Asciak, C.R. (1990) *Biochem. Biophys. Res. Commun.* 171, 944–948.
- [4] Hatzelman, A., Schatz, M. and Ullrich, V. (1989) *Eur. J. Biochem.* 180, 527–533.
- [5] Weitzel, F. and Wendel, A. (1993) *J. Biol. Chem.* 268, 6288–6292.
- [6] Schnurr, K., Belkner, J., Ursini, F., Schwew, T. and Kühn, H. (1996) *J. Biol. Chem.* 271, 4653–4658.
- [7] Imai, H., Narashima, K., Arai, M., Sakamoto, H., Chiba, N. and Nakagawa, Y. (1998) *J. Biol. Chem.* 273, 1990–1997.
- [8] Bryant, R.W., Simon, T.C. and Bailey, J.M. (1982) *J. Biol. Chem.* 257, 14937–14943.
- [9] Sutherland, M., Shankaranarayanan, P., Schewe, T. and Nigam, S. (2001) *Biochem. J.* 353, 91–100.
- [10] Ho, Y.S., Magnenat, J.L., Bronson, R.T., Cao, J., Gargano, M., Sugawara, M. and Funk, C.D. (1997) *J. Biol. Chem.* 272, 16644–16651.
- [11] Reynaud, D., Demin, P. and Pace-Asciak, C.R. (1994) *J. Biol. Chem.* 269, 23976–23980.
- [12] Pace-Asciak, C.R., Reynaud, D. and Demin, P. (1995) *J. Lipid Mediat. Cell Signal.* 12, 307–311.
- [13] Tiedge, M., Lortz, S., Drinkgern, J. and Lenzen, S. (1997) *Diabetes* 46, 1733–1742.
- [14] Garssen, G.J., Veldink, G.A., Vliegthart, J.F. and Boldingh, J. (1976) *Eur. J. Biochem.* 62, 33–36.
- [15] Bryant, R.W., Schewe, T., Rapoport, S.M. and Bailey, J.M. (1985) *J. Biol. Chem.* 260, 3548–3555.
- [16] Shimizu, T., Radmark, O. and Samuelsson, B. (1984) *Proc. Natl. Acad. Sci. USA* 81, 689–693.
- [17] Reynaud, D., Ali, M., Demin, P. and Pace-Asciak, C.R. (1999) *J. Biol. Chem.* 274, 28213–28218.
- [18] Bryant, R.W., Simon, T.C. and Bailey, J.M. (1983) *Biochem. Biophys. Res. Commun.* 117, 183–189.
- [19] Pace-Asciak, C.R. (1984) *Biochem. Biophys. Acta* 793, 485–488.
- [20] Pace-Asciak, C.R., Reynaud, D. and Demin, P. (1995) *Lipids* 30, 107–114.